CLASS III Device recall · Reported 28 Dec 2016 · FDA Enforcement Report

Delfia hFSH kit recalled by PerkinElmer Health Sciences

PerkinElmer Health Sciences is recalling Delfia hFSH kit, distributed in California, Colorado, New York, Washington. The recall was initiated on 16 Nov 2016 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot Number: 646091
Quantity recalled79 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0779-2017
FDA event ID
75708
Recalling firm
PerkinElmer Health Sciences, Waltham, MA
Classification
Class III
Status
Terminated
Recall initiated
16 Nov 2016
FDA classified
16 Dec 2016
Reported
28 Dec 2016
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

16 Nov 2016Recall initiated by company
16 Dec 2016Classified by FDA+30 days
28 Dec 2016Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

A DELFIA hFSH kit lot failed real time stability testing. The real time stability data demonstrated a decrease in hFSH concentrations between -4.8% to -11.3% for control sera. The -11.3% bias was observed at an hFSH target concentration of 101 IU/L. The change observed in the serum samples within the range 1.76  67.0 IU/L hFSH averaged -2.9%. The reference range of the assay spans 0.60 to 98.0 IU/L.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

DELFIA hFSH kit. In Vitro Diagnostic for the determination of hFSH in serum

Where it was distributed

CA, CO, NY, WA Foreign: Austria, Bolivia, Bosnia , Sweden, Norway, Netherlands, Japan, Great Britain,

CaliforniaColoradoNew YorkWashington

Questions about this recall

Why was it recalled?

A DELFIA hFSH kit lot failed real time stability testing. The real time stability data demonstrated a decrease in hFSH concentrations between -4.8% to -11.3% for control sera. The -11.3% bias was observed at an hFSH target concentration of 101 IU/L. The change observed in the serum samples within the range 1.76  67.0 IU/L hFSH averaged -2.9%. The reference range of the assay spans 0.60 to 98.0 IU/L.

Which lots are affected?

Lot Number: 646091

Where was it sold?

CA, CO, NY, WA Foreign: Austria, Bolivia, Bosnia , Sweden, Norway, Netherlands, Japan, Great Britain,

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from PerkinElmer Health Sciences

All 10

Other Test Kits & Diagnostics recalls

All 2,658